Dyax

www.dyax.com
Profile Unclaimed

Dyax Reviews

4 Reviews
3.4
4 Reviews

Recommend to a friend
Approve of CEO
Dyax President, CEO, and Director Gustav A. Christensen
Gustav A. Christensen
1 Rating
  •  

    Dyax is a good place to work.

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Career Opportunities
    Current Employee - Scientist I in Cambridge, MA
    Current Employee - Scientist I in Cambridge, MA

    I have been working at Dyax

    Pros

    The company's culture is very good. Every year employees make a lot donation to charities.

    Cons

    Layoff happened since 3 years ago.

    Recommends
    No opinion of CEO

Dyax Interviews

Interview Experience

Interview Experience

100%
0%
0%

Getting an Interview

Getting an Interview

100%

Interview Difficulty

3.0
Average

Interview Difficulty

Hard

Average

Easy
  1. 1 person found this helpful  

    Senior Scientist Interview

    Anonymous Employee in Boston, MA
    Anonymous Employee in Boston, MA
    Application Details

    I applied online. The process took a dayinterviewed at Dyax in January 2009.

    Interview Details

    HR interview
    presentation
    interview with group
    interview with Director of Dept. and hiring manager
    and HR interview again

    Interview Questions
    No Offer
    Positive Experience
    Average Interview

Dyax Awards & Accolades

Something missing? Add an award
Top Places to Work Globe 100, Boston Globe, 2008

Additional Info

Unlock Profile
Website www.dyax.com
Headquarters Burlington, MA
Size 50 to 149 Employees
Founded 1989
Type Company - Public (DYAX)
Industry Biotech & Pharmaceuticals
Revenue $50 to $100 million (USD) per year

Dyax is arming the war against disease. The biopharmaceutical company develops drugs from its proprietary technology that rapidly identifies proteins, peptides, and antibodies it can use to treat disease, with a primarily focus on oncology and inflammation remedies. Dyax's first commercial drug, Kalbitor (DX-88), has been approved in the US to treat hereditary angioedema (HAE, a condition causing tissue swelling) in patients 16 and older. DX-88 is being investigated for additional indications. The company has other product candidates in discovery and development stages... More

Work at Dyax? Share Your Experiences

Dyax

 
Click to Rate
or